NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced it will present data from its preclinical MALT1 inhibitor program at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition to be held virtually December 5-8, 2020.
MALT1 is a potential therapeutic target for non-Hodgkin’s B-cell lymphomas (NHL), chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), which are areas of high unmet medical need, especially in relapsed/refractory settings. Schrödinger has identified novel MALT1 inhibitors, which have shown antiproliferative effects in non-Hodgkin’s B-cell lymphoma models in preclinical studies.
Dose-dependent single agent anti-tumor activity was observed in a mouse xenograft model of B-cell lymphoma with the novel MALT1 inhibitors. When combined with ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, the activity observed supports the potential for MALT1 inhibitors to be used in combination to overcome drug-induced resistance in patients with relapsed/refractory B-cell lymphoma.
“We look forward to sharing our updated MALT1 results and advancing the program to IND-enabling studies in the coming year,” said Karen Akinsanya, Ph.D., Executive Vice President, Chief Biomedical Scientist and Head of Discovery R&D at Schrödinger. “We are proud of the rapid progress we have made on our MALT1 program. Our physics-based software platform helped to accelerate compound optimization, enabling candidate selection in under two years.”
The abstract is available online on the ASH website and will be presented at the poster session in December.
Poster session details follow:
Publication # 1175, “Identification of Potent Paracaspase MALT1 Inhibitors for Hematological Malignancies”
Date: Saturday, December 5, 2020
Time: 7:00 a.m. to 3:30 p.m. PT, Session #625
Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages its software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.
Founded in 1990, Schrödinger has over 400 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com and follow us on LinkedIn and Twitter.
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those regarding the clinical potential and favorable properties of our MALT1 inhibitor program, the potential for MALT1 inhibitors to be used alone or in combination with BTK inhibitors to treat B-cell malignancies, the timing of potential IND-enabling studies for our MALT1 program, and the potential of our platform to enable the discovery of high-quality, novel molecules for drug development and materials applications. Statements including words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "look forward," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," "would" and statements in the future tense are forward-looking statements. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including the uncertainties inherent in early stage drug development, including the conduct of research activities, the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies; the timing of and our ability to submit and obtain regulatory approval for investigational new drug applications; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials, as well as the other risks and uncertainties identified under the caption "Risk Factors" and elsewhere in our Securities and Exchange Commission filings and reports, including the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 10, 2020, as well as future filings and reports by us. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, we undertake no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise.
Ten Bridge Communications
Stern IR, Inc.